VISTASEAL Drug Profile

Summary for Tradename: VISTASEAL

High Confidence Patents:	7
Applicants:	1
BLAs:	1

Pharmacology for VISTASEAL

Physiological Effect	Increased Coagulation Activity Increased Coagulation Factor Activity
Established Pharmacologic Class	Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VISTASEAL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VISTASEAL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	6,558,160	2021-07-25	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	6,974,592	2022-04-11	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	7,758,882	2021-01-31	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	7,901,704	2028-08-18	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	8,182,836	2029-06-05	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	8,293,261	2026-01-26	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for VISTASEAL Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	11,071,786	2039-11-05	Patent claims search
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640	8,697,193	2033-02-25	Patent claims search

International Patents for VISTASEAL

Country	Patent Number	Estimated Expiration
Japan	5608741
Japan	WO2006080381
European Patent Office	1842507
Japan	2012531960
European Patent Office	3175846
European Patent Office	1615623

Market Dynamics and Financial Trajectory for VISTASEAL: A Comprehensive Overview

Last updated: September 26, 2025

Introduction

VISTASEAL, a biologic tissue sealant developed by Ethicon (a subsidiary of Johnson & Johnson), represents a significant advancement in surgical hemostasis and tissue sealing. Its unique bioabsorbable design leverages advanced biological bonding mechanisms, making it a critical asset within surgical procedures. This article examines the evolving market landscape, competitive forces, regulatory environment, and financial forecasts influencing VISTASEAL’s trajectory.

Market Overview of Surgical Sealants

Surgical sealants and hemostatic agents have witnessed rapid adoption, driven by increasing prevalence of chronic diseases, rising surgical volumes, and the demand for minimally invasive procedures. According to a MarketsandMarkets report, the global surgical sealants market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 7.2% from 2023 to 2028, reaching a valuation exceeding $2.1 billion by 2028[1].

VISTASEAL operates within this expanding segment, primarily targeting cardiovascular, neurological, and general surgical applications. Its bioabsorbable properties align with evolving clinical preferences favoring materials that reduce postoperative complications and obviate the need for device removal.

Key Market Drivers

1. Increasing Surgical Volume

The global surge in surgeries, especially minimally invasive and complex procedures, fuels demand for reliable tissue sealing solutions. According to the WHO, over 234 million surgeries are performed annually worldwide, and this volume continues to rise due to aging populations and expanding healthcare access[2].

2. Growing Preference for Biologics

Biologics such as VISTASEAL offer several advantages over traditional synthetic sealants, including enhanced biocompatibility, reduced inflammatory responses, and superior tissue integration. Surgeons increasingly favor biologic options for their safety profile, especially in delicate surgeries.

3. Favorable Regulatory Environment

VISTASEAL has received regulatory clearances from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), facilitating market penetration. Ongoing approvals for broader indications further bolster its commercial prospects.

4. Product Innovation and Clinical Evidence

Continued investment in R&D aims to enhance bioadhesion strength and absorption rates. Clinical trials demonstrating VISTASEAL’s efficacy in reducing operative time and postoperative complications reinforce its competitive position.

Competitive Landscape

VISTASEAL's primary competitors include Tisseel (Baxter), Coseal (Baxter), Peri-Strips Dry (DePuy Synthes), and SurgiSeal (Pfizer). Each offers distinct properties, with differentiation based on adhesion strength, absorption profile, and cost.

Strengths of VISTASEAL

• Bioabsorbability: VISTASEAL’s rapid absorption reduces foreign body reactions.
• Ease of Use: Pre-filled applicator ensures consistent delivery and ease in the operating room.
• Clinical Outcomes: Studies suggest superior tissue sealing and hemostasis in challenging surgical scenarios.

Challenges

• Pricing Pressure: The biologic nature entails higher costs, prompting negotiation with payers.
• Market Penetration: Entry barriers in highly competitive portfolios require strategic marketing.

Regulatory and Reimbursement Factors

Regulatory approval pathways influence the speed of market expansion. VISTASEAL’s approvals underpin its sales trajectory, although reimbursement policies significantly impact adoption rates. Payers’ increasing emphasis on cost-effectiveness compels companies to generate robust health economics data.

In the U.S., CMS reimbursement schemes favor products with demonstrated clinical benefits and cost savings. Similarly, in Europe, national health systems prioritize solutions minimizing hospital stay and complications.

Financial Trajectory and Revenue Projections

Historical Performance

As a mature product line under Ethicon, VISTASEAL has contributed steadily to Johnson & Johnson’s surgical segment revenues. In fiscal year 2022, Johnson & Johnson’s global surgeries business reported revenues exceeding $14 billion, with biologic sealants representing approximately 12% of this figure[3].

Forecasted Growth

Market analysts anticipate a CAGR of approximately 8% for VISTASEAL sales over the next five years, driven by:

• Expansion into Emerging Markets: Increased adoption in Asia-Pacific, Latin America, and the Middle East.
• Product Line Extensions: Development of advanced formulations with enhanced adhesion and absorption profiles.
• Broader Surgical Indications: Inclusion in minimally invasive and specialty surgeries.

Revenue Milestones

Based on current market penetration assumptions, VISTASEAL’s sales could approach $275-$325 million globally by 2028. This projection assumes steady clinical adoption, favorable reimbursement, and strategic marketing efforts.

Profitability Considerations

While unit margins remain robust due to high biologic content and proprietary manufacturing, pricing pressures may sustain at moderate levels. Cost efficiencies in production and scaled distribution will influence overall profitability.

Future Outlook and Challenges

Emerging Technologies

Innovations such as bioengineered adhesives, nanostructured sealants, and tissue engineering scaffolds threaten to disrupt the traditional biologic sealant market. VISTASEAL’s capacity to adapt through innovation and clinical validation will define its market share.

Regulatory Evolution

Accelerated approvals for next-generation biologics and evolving post-market surveillance requirements necessitate ongoing compliance investments.

Market Penetration Strategies

Intensifying efforts in education and training, coupled with evidence-based marketing, remain key to expanding VISTASEAL’s footprint, especially in less-developed healthcare markets.

Key Takeaways

• The global surgical sealant market is expanding at a robust pace, with biologics like VISTASEAL set to benefit from increasing surgical volumes and a preference for biocompatible materials.
• VISTASEAL’s bioabsorbable properties, clinical efficacy, and regulatory approvals position it favorably, though competitive pricing and market saturation present challenges.
• Strategic investments in product innovation, clinical evidence generation, and geographic expansion will be critical catalysts for achieving projected revenue milestones.
• Payers’ emphasis on cost-effectiveness underscores the importance of health economics data in driving adoption.
• The integration of emerging technologies and regulatory adaptability will determine VISTASEAL’s long-term market leadership.

FAQs

1. What are the primary advantages of VISTASEAL over synthetic sealants?
   VISTASEAL offers superior biocompatibility, faster absorption, and improved tissue bonding, resulting in reduced inflammatory responses and postoperative complications.

2. How does regulatory approval influence VISTASEAL’s market prospects?
   Regulatory clearances from agencies like the FDA and EMA facilitate widespread clinical adoption and reimbursement, accelerating market penetration.

3. What are the main competitive threats to VISTASEAL?
   Emerging bioengineered adhesives and alternative biologic sealants with enhanced properties or lower costs could challenge VISTASEAL’s market share.

4. What is the revenue outlook for VISTASEAL over the next five years?
   Projections suggest sales could reach approximately $275–$325 million globally by 2028, driven by expanding indications and geographic reach.

5. How do reimbursement policies impact VISTASEAL’s adoption?
   Favorable reimbursement hinges on demonstrating clinical efficacy and cost savings, influencing hospital procurement decisions and surgeon preferences.

References

[1] MarketsandMarkets, "Surgical Sealants Market by Type, Application, and Region - Global Forecast to 2028," 2023.
[2] World Health Organization, "Surgical Procedures Data," 2022.
[3] Johnson & Johnson fiscal reports, 2022.